filgrastim-aafi Nivestym
Selected indexed studies
- Filgrastim. (, 2006) [PMID:30000432]
- Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study. (Drugs Real World Outcomes, 2022) [PMID:36070082]
- Comparison of the efficacy and total cost of peripheral blood stem cell collections in allogeneic donors using either filgrastim (Neupogen®) or filgrastim aafi (Nivestym®). (Transfus Apher Sci, 2025) [PMID:40483042]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Filgrastim. (2006) pubmed
- Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study. (2022) pubmed
- Comparison of the efficacy and total cost of peripheral blood stem cell collections in allogeneic donors using either filgrastim (Neupogen®) or filgrastim aafi (Nivestym®). (2025) pubmed
- Real-World Noninferiority Assessment of Two Filgrastim Biosimilars in Patients Receiving Myelosuppressive Chemotherapy. (2025) pubmed
- PF-06881893 (Nivestym™), a Filgrastim Biosimilar, Versus US-Licensed Filgrastim Reference Product (US-Neupogen(®)): Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers. (2019) pubmed